Identification and characterization of novel candidate compounds targeting 6‐ and 7‐transmembrane μ‐opioid receptor isoforms

Abstract

Background and Purpose The μ‐opioid receptor (μ receptor) is the primary target for opioid analgesics. The 7‐transmembrane (TM) and 6TM μ receptor isoforms mediate inhibitory and excitatory cellular effects. Here, we developed compounds selective for 6TM‐ or 7TM‐μ receptors to further our understanding of the pharmacodynamic properties of μ receptors. Experimental Approach We performed virtual screening of the ZINC Drug Now library of compounds using in silico 7TM‐ and 6TM‐μ receptor structural models and identified potential compounds that are selective for 6TM‐ and/or 7TM‐μ receptors. Subsequently, we characterized the most promising candidate compounds in functional in vitro studies using Be2C neuroblastoma transfected cells, behavioural in vivo pain assays using various knockout mice and in ex vivo electrophysiology studies. Key Results Our virtual screen identified 30 potential candidate compounds. Subsequent functional in vitro cellular assays shortlisted four compounds (#5, 10, 11 and 25) that demonstrated 6TM‐ or 7TM‐μ receptor‐dependent NO release. In in vivo pain assays these compounds also produced dose‐dependent hyperalgesic responses. Studies using mice that lack specific opioid receptors further established the μ receptor‐dependent nature of identified novel ligands. Ex vivo electrophysiological studies on spontaneous excitatory postsynaptic currents in isolated spinal cord slices also validated the hyperalgesic properties of the most potent 6TM‐ (#10) and 7TM‐μ receptor (#5) ligands. Conclusion and Implications Our novel compounds represent a new class of ligands for μ receptors and will serve as valuable research tools to facilitate the development of opioids with significant analgesic efficacy and fewer side‐effects.

Structure-based discovery of nonopioid analgesics acting through the α 2A -adrenergic receptor

“…2777), and 7- to 8-week-old females were used. Sample sizes were modeled on our previous studies and on studies using a similar approach, which were able to detect significant changes ( 96 , 97 ). The animals were randomly assigned to treatment and control groups.…”

Large library docking for cannabinoid-1 receptor agonists with reduced side effects

“…Mice were housed in cages on a standard 12:12 hour light/dark cycle with food and water ad libitum. Sample sizes were modelled on our previous studies and on studies using a similar approach, which were able to detect significant changes 74, 75 . The animals were randomly assigned to treatment and control groups.…”

“…5). The final refinement parameters are provided in able to detect significant changes 74,75 . The animals were randomly assigned to treatment and control groups.…”

“…Compound '3234 was further tested at 1 µM for off-target activity at a panel of 45 common GPCR and non-Animal experiments were approved by the UCSF Institutional Animal Care and Use Committee and were conducted in accordance with the NIH Guide for the Care and Use of Laboratory animals (protocol #AN195657). detect significant changes74,75 . The animals were randomly assigned to treatment and control groups.…”

Up‐regulation of oxytocin receptors on peripheral sensory neurons mediates analgesia in chemotherapy‐induced neuropathic pain

“…In all statistical analyses, the group size was used as the number of independent values (i.e., technical replicates were not used as independent values). The sample size was calculated based on the previously published studies that applied the same methods of quantifications (Donnelly et al, 2021;Jiang et al, 2020;Muralidharan et al, 2021). All data were assessed for normality using the Shapiro-Wilk test, with a P-value greater than 0. restricted within DRG neurons that were classified by Nissl (Figure 1b,c).…”